Basic Information
Vpriv
Regulatory Information
EMEA/H/C/001249
Authorised
August 26, 2010
June 4, 2010
20
August 8, 2023
Company Information
Ireland
Block 2 Miesian Plaza 50-58 Baggot Street Lower Dublin 2 Co Dublin D02 HW68
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Drug Classification
Accelerated Assessment
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Vpriv. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vpriv.